What did @aleyadean1 actually say?
Honestly, not much that can be fact-checked in the traditional sense. The transcript is largely inaudible or garbled, producing phrases like "shows the we are united" and "run my home time" that appear to be transcription artifacts rather than actual speech. What we do have is the caption, which frames this as a "shot day" post on Mounjaro, celebrates the GLP-1 community, and encourages other users to be open about their treatment journey. There are no clinical claims in the text. The video is personal documentation, not medical advice.
That matters, because the fact-check has to be honest about what it is working with. The creator is sharing an injection day moment, not telling followers to take a specific drug or dose. That is a meaningful distinction.
Does the science back up the broader GLP-1 weight loss narrative?
For tirzepatide specifically, which Mounjaro contains, the evidence is strong. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks, compared to 3.1% on placebo. That is not a modest effect. It is one of the largest weight reductions ever observed in a pharmacological trial for obesity.
But here is what the community posts often flatten: these results came with structured diet and lifestyle counseling, not tirzepatide alone. Side effect burden, including nausea, vomiting, and gastrointestinal distress, led to discontinuation in roughly 4-5% of participants. Long-term data beyond two years is still limited. The drug works. How it works in real-world conditions, without trial-level support, is a separate and still-open question.
What did the creator get wrong, or right?
Right: normalizing the physical reality of being on a GLP-1 medication, including showing the abdomen used for subcutaneous injection, is genuinely useful. Stigma around both obesity and injectable medication is a documented barrier to treatment access (Puhl and Heuer, 2010, Obesity Reviews). Posts that reduce that stigma have real value.
Wrong, or at least incomplete: the "GLP-1 girlies doing the damn thing" framing implicitly positions these medications as straightforward wins. There is no mention of the fact that tirzepatide requires a prescription, medical supervision, and careful screening for contraindications including personal or family history of medullary thyroid carcinoma or MEN2 syndrome. The FDA prescribing information for Mounjaro carries a boxed warning on this. A 380,000-view post reaching people who may be considering starting a GLP-1 without a physician could use that context, even briefly.
What should you actually know about GLP-1 treatment and social media?
GLP-1 receptor agonist content has exploded on TikTok and Instagram, and most of it is positive. That creates a selection bias problem. People whose treatment is going well post. People who discontinued due to side effects, or who gained weight back after stopping, post far less frequently. A 2023 analysis of GLP-1 content on social media (Talbot et al., 2023, Journal of Medical Internet Research) found that the majority of posts emphasized benefits and minimized risks, regardless of whether the poster was a licensed clinician.
What that means for you: individual results vary substantially. Tirzepatide and semaglutide are real drugs with real efficacy data, but also real contraindications, real costs, and real rebound weight gain rates when discontinued without lifestyle changes. The STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism) found that participants regained two-thirds of lost weight within one year of stopping semaglutide. That fact almost never makes it into shot day posts.
- GLP-1 medications require a valid prescription and ongoing medical supervision.
- Compounded versions of semaglutide or tirzepatide are not equivalent to FDA-approved brand-name drugs and carry additional regulatory and safety considerations.
- Social media success stories do not represent the full distribution of outcomes.
The bottom line
This video is a personal celebration, not a medical tutorial, and it should be evaluated as such. The creator is not making false clinical claims. But with 380,000 views, the implicit message that GLP-1 treatment is uncomplicated and universally positive reaches a lot of people who deserve the fuller picture. Enthusiasm is not misinformation. Enthusiasm without context can function like it.